WebAug 18, 2024 · This is an open-label, randomized, multi-site, Phase II, interventional trial designed to evaluate the efficacy, tolerability, and safety of BNT111 + cemiplimab in anti-PD-1-refractory/relapsed patients with unresectable Stage III or IV melanoma. The contributions of BNT111 and cemiplimab will be delineated in single agent calibrator arms. WebSep 12, 2024 · BioNTech’s promising melanoma vaccine (BNT111), for example, has advanced to Phase II trials. But researchers hope to treat a broader range of cancers, known as cold tumors, that do not respond as well to immunotherapy. Fortunately, an influx of funding for COVID vaccines has given mRNA cancer research a shot in the arm.
Biontech & MRNA: Revolution in der Pharmaindustrie
WebJan 13, 2024 · BNT111 focuses on four particular melanoma antigens. The company says at least one of those four antigens can be found in more than 90 percent of skin cancers. Phase 1 trials found BNT111... WebTrial phase: Phase II Studienambulanz der Hautklinik 0911-398-3864 Clinical Trials register - Search for BNT111-01 Malignes Melanom NivoMela Malignes Melanom, Stadium II Adjuvant Patients will be screened using the MelaGenix GEP; patients with high risk score will be randomized at a ratio of 2:1 to receive either nivolumab as oval garnet and diamond ring
BioNTech Publishes Data from mRNA-based BNT111 FixVac …
WebJul 30, 2024 · -- Preliminary Phase 1 results from Lipo-MERIT trial with data from 89 patients highlight favorable tolerability profile of BNT111 in advanced melanoma patients -- Efficacy analysis in a subset of 42 checkpoint-inhibitor (CPI)-experienced metastatic melanoma patients shows that BNT111 mediates durable responses both as a single … WebAug 26, 2024 · Trial With BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Anti-PD-1-refractory/Relapsed, Unresectable Stage III or IV Melanoma. The safety and scientific validity of this study is the responsibility of the … WebOct 1, 2024 · Program: BNT111 Poster Title: An RNA lipoplex (RNA-LPX) vaccine demonstrates strong immunogenicity and promising clinical activity in a Phase I trial in cutaneous melanoma patients with no evidence of disease at trial inclusion Abstract Number: 15965 Date & Time: Friday, November 12, 2024, 7:00 am - 8:30 pm ET. … oval gingham tablecloth